A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 4,921 shares of BGNE stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,921
Holding current value
$1.01 Million
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$129.52 - $174.32 $637,367 - $857,828
4,921 New
4,921 $702,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $21.3B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Mirae Asset Global Etfs Holdings Ltd. Portfolio

Follow Mirae Asset Global Etfs Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Etfs Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Etfs Holdings Ltd. with notifications on news.